Immunogen Cash Flow | StatInvestor

Health Care & Life Sciences » Biotechnology | Immunogen Inc.

Immunogen Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

72,811.00

71,364.00

60,739.00

78,883.00

96,012.00

168,843

Depreciation, Depletion & Amortization

4,641.00

4,598.00

5,513.00

3,074.00

5,963.00

7,411

Other Funds

194,135.00

1,699.00

4,696

Funds from Operations

55,746.00

37,541.00

39,356.00

70,483.00

69,939.00

166,128

Changes in Working Capital

4,553.00

16,109.00

15,935.00

13,173.00

77,584.00

294

Net Operating Cash Flow

60,299.00

53,650.00

55,291.00

83,656.00

7,645.00

166,422

Capital Expenditures

3,770.00

8,184.00

7,425.00

1,406.00

1,116.00

Net Investing Cash Flow

3,696.00

8,185.00

7,425.00

1,406.00

1,116.00

Net Financing Cash Flow

98,017.00

9,136.00

198,564.00

100,614.00

Net Change in Cash

34,022.00

52,699.00

135,848.00

85,062.00

107,143.00

Free Cash Flow

64,069.00

61,834.00

62,716.00

85,062.00

6,529.00

Other Sources

74.00

Change in Capital Stock

98,017.00

9,136.00

4,429.00

102,313.00

Other Uses

1.00

About Immunogen

View Profile

Address	830 Winter Street Waltham Massachusetts 02451 United States
Employees	-
Website	http://www.immunogen.com
Updated	07/08/2019
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.